Alteration of putaminal fractional anisotropy in Parkinson’s disease: a longitudinal diffusion kurtosis imaging study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1432-1920
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Alteration of putaminal fractional anisotropy in Parkinson’s disease: a longitudinal diffusion kurtosis imaging study ; volume:60 ; number:3 ; day:24 ; month:1 ; year:2018 ; pages:247-254 ; date:3.2018
Neuroradiology ; 60, Heft 3 (24.1.2018), 247-254, 3.2018
- Schlagwort
-
Hirnkrankheit
Neuropsychiatrie
Nervenkrankheit
- Urheber
-
Surova, Yulia
- Beteiligte Personen und Organisationen
-
Nilsson, Markus
Lampinen, Björn
Lätt, Jimmy
Hall, Sara
Widner, Håkan
Westen, Danielle van
Hansson, Oskar
SpringerLink (Online service)
- DOI
-
10.1007/s00234-017-1971-3
- URN
-
urn:nbn:de:1111-201804017178
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:00 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Surova, Yulia
- Nilsson, Markus
- Lampinen, Björn
- Lätt, Jimmy
- Hall, Sara
- Widner, Håkan
- Westen, Danielle van
- Hansson, Oskar
- SpringerLink (Online service)
Ähnliche Objekte (12)
Factors associated with fear of falling in people with Parkinson’s disease
The clinical significance of 10-m walk test standardizations in Parkinson’s disease
External validation of a 3-step falls prediction model in mild Parkinson’s disease
18F-AV-1451 in Parkinson’s Disease with and without dementia and in Dementia with Lewy Bodies
Comparison of risk factors for Parkinson’s disease, coronary events and ischemic stroke
Cerebrospinal fluid concentrations of inflammatory markers in Parkinson’s disease and atypical parkinsonian disorders
Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer’s and Parkinson’s disease
Effects of certain pre-analytical factors on the performance of plasma phospho-tau217
Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease
Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer’s disease
Characterization of degradation and heterozygote balance by simulation of the forensic DNA analysis process
Convolutional neural network optimizes the application of diffusion kurtosis imaging in Parkinson’s disease
Factors associated with fear of falling in people with Parkinson’s disease
The clinical significance of 10-m walk test standardizations in Parkinson’s disease
External validation of a 3-step falls prediction model in mild Parkinson’s disease
18F-AV-1451 in Parkinson’s Disease with and without dementia and in Dementia with Lewy Bodies
Comparison of risk factors for Parkinson’s disease, coronary events and ischemic stroke
Cerebrospinal fluid concentrations of inflammatory markers in Parkinson’s disease and atypical parkinsonian disorders
Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer’s and Parkinson’s disease
Effects of certain pre-analytical factors on the performance of plasma phospho-tau217
Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease
Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer’s disease
Characterization of degradation and heterozygote balance by simulation of the forensic DNA analysis process
Convolutional neural network optimizes the application of diffusion kurtosis imaging in Parkinson’s disease
Factors associated with fear of falling in people with Parkinson’s disease
The clinical significance of 10-m walk test standardizations in Parkinson’s disease
External validation of a 3-step falls prediction model in mild Parkinson’s disease
18F-AV-1451 in Parkinson’s Disease with and without dementia and in Dementia with Lewy Bodies
Comparison of risk factors for Parkinson’s disease, coronary events and ischemic stroke
Cerebrospinal fluid concentrations of inflammatory markers in Parkinson’s disease and atypical parkinsonian disorders
Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer’s and Parkinson’s disease
Effects of certain pre-analytical factors on the performance of plasma phospho-tau217
Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease
Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer’s disease
Characterization of degradation and heterozygote balance by simulation of the forensic DNA analysis process